Loading clinical trials...
Loading clinical trials...
A Randomized, Double Blind, Placebo-Controlled, Multiple Dose Escalation, Phase 2 Study to Evaluate the Safety, Tolerance, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Preliminary Efficacy of CM326 in Patients With Moderate-severe Atopic Dermatitis Subjects
Conditions
Interventions
CM326
Placebo
Locations
1
China
Peking University People's hospital
Beijing, Beijing Municipality, China
Start Date
February 17, 2022
Primary Completion Date
January 1, 2023
Completion Date
January 1, 2023
Last Updated
March 9, 2022
NCT07321951
NCT03057860
NCT06158490
NCT07344051
NCT05590585
NCT05899816
Lead Sponsor
Keymed Biosciences Co.Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions